Jennifer Jarrett
CIK 1671311 · Director, President and CEO · last filed 2026-09-28
Jennifer Jarrett is a Director, President and CEO who has filed 86 SEC Form 4 insider transactions across 11 companies since 2016. The most recent filing shows the insider bought $252.9K of DMRA on Sep 28, 2026. Across all open-market trades the lifetime net is −$11.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.4M across reported positions. 7 SEC filings were submitted jointly with ARENA PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RCUS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
525 MARKET ST., 36TH FLOOR
SAN FRANCISCO, CA 94105
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DMRA | Director, President and CEO | 512,500 | $21.26 | $10.90M | $252.9K | 2 | 2026-09-28 |
| ZURA | Director | — | $3.56 | — | $0 | 3 | 2026-06-22 |
| SGMT | Director | — | $9.56 | — | $0 | 3 | 2026-06-15 |
| SNDX | Director | 114,000 | $13.22 | $1.51M | $0 | 9 | 2026-02-06 |
| RCUS | Chief Operating Officer | 224,024 | $17.76 | $3.98M | -$11.77M | 39 | 2026-01-26 |
| Zura Bio Ltd (ZURAW) Delisted | Director | — | $1.08 | — | $0 | 1 | 2023-05-22 |
| Radius Health, Inc. (RDUS) Delisted | Director | — | $30.00 | — | $0 | 2 | 2022-08-15 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | Director | 3,067 | $99.99 | $306.7K | $0 | 6 | 2022-03-11 |
| Surrozen, Inc./DE (SRZNW) Delisted | 30,000 | $0.00 | $45 | $0 | 1 | 2021-08-13 | |
| BOLD | Director | — | $2.41 | — | $0 | 5 | 2020-01-15 |
| MEDIVATION, INC. (MDVN) Delisted | Chief Financial Officer | 29,971 | — | — | $0 | 1 | 2016-04-08 |
Recent Filings
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-28 | DMRA | Buy (P) | +12,500 | $252.9K | EDGAR |
| 2026-06-22 | ZURA | Grant (A) | — | $0 | EDGAR |
| 2026-06-15 | SGMT | Grant (A) | — | $0 | EDGAR |
| 2026-05-06 | RCUS | Notice (144) | −77,793 | -$1.91M | EDGAR |
| 2026-04-23 | RCUS | Notice (144) | −53,826 | -$1.36M | EDGAR |
| 2026-04-08 | RCUS | Notice (144) | −70,000 | -$1.58M | EDGAR |
| 2026-04-01 | DMRA | Grant (A) | +500,000 | $0 | EDGAR |
| 2026-02-06 | SNDX | Grant (A) | +24,000 | $0 | EDGAR |
| 2026-01-26 | RCUS | Grant (A) | +31,000 | $0 | EDGAR |
| 2025-12-18 | RCUS | Sell (S) | −21,208 | -$466.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.